SHR-1210
Phase 2UNKNOWN 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Extranodal NK/T-cell Lymphoma, Nasal Type
Conditions
Extranodal NK/T-cell Lymphoma, Nasal Type
Trial Timeline
May 29, 2018 → Jun 1, 2021
NCT ID
NCT03363555About SHR-1210
SHR-1210 is a phase 2 stage product being developed by Jiangsu Hengrui Medicine for Extranodal NK/T-cell Lymphoma, Nasal Type. The current trial status is unknown. This product is registered under clinical trial identifier NCT03363555. Target conditions include Extranodal NK/T-cell Lymphoma, Nasal Type.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (9)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03558191 | Phase 2 | Completed |
| NCT03557411 | Phase 2 | UNKNOWN |
| NCT03363555 | Phase 2 | UNKNOWN |
| NCT03222440 | Pre-clinical | Completed |
| NCT03155425 | Phase 2 | Completed |
| NCT03085069 | Phase 2 | UNKNOWN |
| NCT02989922 | Phase 2 | Completed |
| NCT02738489 | Phase 1 | Completed |
| NCT02721589 | Phase 1 | Completed |
Competing Products
8 competing products in Extranodal NK/T-cell Lymphoma, Nasal Type
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Avastin + Gemcitabine + Oxaliplatin + Pegaspargase + Dexamethasone | Eli Lilly | Phase 2 | 52 |
| High dose of methotrexate + Gemcitabine + Pegaspargase + Dexamethasone | Eli Lilly | Phase 2 | 52 |
| Camrelizumab | Jiangsu Hengrui Medicine | Phase 2 | 52 |
| avelumab | Merck | Phase 2 | 52 |
| Pembrolizumab | Merck | Phase 2 | 52 |
| PI3K inhibitor BKM120 + rituximab | Novartis | Phase 1 | 33 |
| carfilzomib | Amgen | Phase 1 | 32 |
| IBI318(Recombinant human anti-PD1/PD-L1 bispecific antibody) | Innovent Biologics | Phase 1/2 | 40 |